Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Dr. Reddy’s Laboratories Limited (“Dr. Reddy’s” or the “Company”) (NYSE: RDY) concerning possible violations of federal securities laws.
To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or by email at brian@lundinlawpc.com.
On November 6, 2015, Dr. Reddy’s announced that it received a warning letter issued by the U.S. Food and Drug Administration concerning inadequate quality control standards at three of the Company’s manufacturing plants in India. On this news, shares of Dr. Reddy’s fell in value. On August 10, 2017, the Company disclosed that the Regulatory of Germany (Regierung von Oberbayern) did not renew the good manufacturing practices compliance certificate of a formulations manufacturing unit of its German subsidiary Betapharm Arzneimittel, located in Hyderabad, India, following a recent inspection of the plant. Upon release of this information, shares of Dr. Reddy’s fell in value.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170814005984/en/
Contacts:
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile:
888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/
